close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Athira Pharma, Inc. - Common Stock (NQ:ATHA)

6.750 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Athira Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Sidoti Events, LLC's Virtual December Small-Cap Conference
Via ACCESSWIRE
News headline image
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
News headline image
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS) 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
Data presented at Society for Neuroscience Annual Meeting 2023 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Participate in Jefferies London Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Participate in Upcoming October Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
Three poster presentations to highlight clinical and preclinical data across Athira’s pipeline of neuroprotective therapeutic candidates 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Participate in Upcoming June Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experience 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Participate in Upcoming May Investor Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET system 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
Company to highlight potential of its small molecule therapeutics that enhance the HGF/MET system to treat a variety of neurodegenerative diseases 
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma, Inc. (NASDAQ:ATHA) Investor Alert: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 03/06/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Athira Pharma, Inc. 
Via SBWire
News headline image
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
News headline image
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
From Athira Pharma, Inc.
Via GlobeNewswire
News headline image
NASDAQ:ATHA Shareholder Notice: Update in Lawsuit Against Athira Pharma, Inc. ↗
San Diego, CA -- (SBWIRE) -- 01/18/2023 -- The Shareholders Foundation announced an update in the lawsuit that was filed on behalf of certain investors in Athira Pharma, Inc. (NASDAQ:ATHA). 
Via SBWire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today